多黏菌素B血液吸附用于内毒素性脓毒性休克的共识推荐
该共识采用改良德尔菲法,由十名重症与肾脏病专家经会前问卷、一天面对面会议及多轮投票形成,共识阈值定为≥80%同意。共达成20条声明,覆盖三方面:疑似或推断脓毒性休克时启动内毒素评估的操作标准、EAA的作用与解读、PMX-HA的实施流程。关键推荐包括:用标准化标准筛选合格患者;EAA≥0.60且<0.90支持考虑PMX-HA;资格确认后尽早开始,以脓毒性休克发生后≤36小时作为务实的实施基准;标准方案为两次治疗、间隔24小时、每次目标120分钟;推荐多学科团队模式实施。研究方向包括疗效异质性、EAA动力学、临床实施和医疗系统整合。
要点
- 共识推荐用标准化操作标准在疑似或推断脓毒性休克患者中启动内毒素评估,以筛选PMX-HA合格人群。
- EAA阈值≥0.60且<0.90支持考虑PMX-HA(共识声明,≥80%同意)。
- 资格确认后应尽早启动PMX-HA,脓毒性休克发生后≤36小时被提出作为务实的实施基准。
- 标准治疗方案为两次治疗、间隔24小时、每次目标120分钟(共识推荐)。
- 共识支持采用多学科团队模式实施PMX-HA。
适用人群与场景
- 疑似或推断脓毒性休克、需评估内毒素血症并考虑PMX-HA的患者。
诊断标准与关键阈值
- EAA阈值≥0.60且<0.90支持考虑PMX-HA(共识声明)。
- 脓毒性休克发生后≤36小时被提出作为启动PMX-HA的务实实施基准。
处置流程与药物剂量
- 按标准化操作标准识别PMX-HA合格患者后,行EAA评估,EAA≥0.60且<0.90支持考虑PMX-HA。
- 资格确认后尽早启动PMX-HA,以脓毒性休克发生后≤36小时作为务实实施基准。
- 标准治疗方案为两次治疗、间隔24小时、每次目标120分钟。
- 采用多学科团队模式实施PMX-HA。
研究设计与关键结果
- 改良德尔菲共识:十名重症与肾脏病专家参与,经会前问卷、一天面对面共识会议及多轮投票,共识阈值≥80%同意。
- 共达成20条声明,覆盖三方面:启动内毒素评估的操作标准、EAA的作用与解读、PMX-HA的后勤与临床实施。
- 关键推荐包括标准化合格患者标准、EAA≥0.60且<0.90支持考虑PMX-HA、尽早启动并以≤36小时为务实基准、两次治疗间隔24小时每次目标120分钟、多学科团队实施。
- 研究优先方向为疗效异质性、EAA动力学、临床实施和医疗系统整合。
证据类型、等级与局限
- 证据类型:改良德尔菲共识(专家意见),共识阈值≥80%同意。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对疑似内毒素性脓毒性休克患者,可按共识采用标准化操作标准启动内毒素评估,并用EAA≥0.60且<0.90支持考虑PMX-HA。
- 资格确认后应尽早启动PMX-HA,脓毒性休克发生后≤36小时被提出作为务实实施基准。
- 实施PMX-HA时采用两次治疗、间隔24小时、每次目标120分钟的标准方案,并以多学科团队模式推进。
- 该框架旨在支持已在用PMX-HA的机构,并协助美国临床医生与医疗系统在监管批准前做好准备。
指南或共识出处
- 多黏菌素B血液吸附用于内毒素性脓毒性休克的共识推荐(Crit Care)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite long-standing clinical use and emerging evidence, no structured framework exists guiding clinicians in identifying septic shock patients for endotoxemia assessment, interpretation of the Endotoxin Activity Assay (EAA), or practical implementation of polymyxin B hemoadsorption (PMX-HA) therapy.
METHODS: A modified Delphi consensus process was conducted with ten critical care and nephrology experts, compromising a pre-meeting survey, a one-day in-person consensus conference, and iterative voting on draft statements. Consensus was predefined as ≥ 80% agreement.
RESULTS: Consensus was achieved on 20 statements across three domains: (1) operational criteria to prompt endotoxemia assessment in suspected or presumed septic shock, (2) role and interpretation of the EAA, and (3) logistics and clinical implementation of PMX-HA. Key recommendations included standardized criteria to identify eligible patients, EAA thresholds of ≥ 0.60 and < 0.90 to support PMX‑HA consideration, initiation of therapy as early as possible once eligibility is confirmed, with ≤ 36 h from septic shock onset proposed as a pragmatic implementation benchmark, and standardized treatment protocols consisting of two sessions, 24 h apart, targeting 120 min each. A multidisciplinary team model was endorsed for implementation. Identified research priorities were in treatment effect heterogeneity, EAA kinetics, clinical implementation, and healthcare system integration.
CONCLUSIONS: These consensus recommendations provide a structured, implementation-focused framework for PMX-HA use in suspected endotoxic shock. The framework emphasizes stepwise operational criteria, biomarker-guided decision-making, multidisciplinary team-based implementation, and standardized protocols. It is intended to support institutions currently using PMX-HA and to assist U.S. clinicians and health systems in preparing for potential adoption pending regulatory approval.
参考来源
- Yessayan, Legrand, Neyra, et al. Consensus recommendations for patient selection and clinical implementation of polymyxin B hemoadsorption in endotoxic septic shock. Crit Care. 2026. PMID: 42928302. doi:10.1186/s13054-026-06182-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。